Compile Data Set for Download or QSAR
Report error Found 922 Enz. Inhib. hit(s) with all data for entry = 10666
TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558265(US11365192, Example 23-2 | N-Methyl-3-[[methyl-[3-...)
Affinity DataIC50: 3nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558426(US11365192, Example 51-1 | Methyl 4-hydroxy-4-[3-[...)
Affinity DataIC50: 3nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558427(US11365192, Example 51-2)
Affinity DataIC50: 3.5nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558428(US11365192, Example 52-1 | 1-[4-Hydroxy-4-[3-[[6-(...)
Affinity DataIC50: 4.40nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558214(US11365192, Example 11-1 | 2,3-Difluoro-5-[3-[[6-(...)
Affinity DataIC50: 5.10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558439(US11365192, Example 58-2 | N-Methyl-N-[[3-[[6-(1H-...)
Affinity DataIC50: 5.10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558313(US11365192, Example 39-1 | 2-[3-[[6-(5-Isothiazoly...)
Affinity DataIC50: 5.30nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558338(US11365192, Example 42-16)
Affinity DataIC50: 5.70nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558218(US11365192, Example 12-1 | 2-Methyl-5-[[6-(1H-pyra...)
Affinity DataIC50: 6.20nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558269(US11365192, Example 23-6)
Affinity DataIC50: 6.40nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558316(US11365192, Example 40-2)
Affinity DataIC50: 6.90nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558216(US11365192, Example 11-3)
Affinity DataIC50: 7.30nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558552(US11365192, Example 75-8 | US11365192, Example 75-...)
Affinity DataIC50: 7.70nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558188(US11365192, Example 6-1 | 1-Acetyl-4-[8-[[6-(1H-py...)
Affinity DataIC50: 7.90nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558451(US11365192, Example 65-1 | 1,1,1-Trifluoro-N-[[3-[...)
Affinity DataIC50: 8.10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558443(US11365192, Example 60-1 | 2,2-Difluoro-2-[3-[[6-(...)
Affinity DataIC50: 8.20nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558158(US11365192, Example 1-63)
Affinity DataIC50: 8.90nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558294(US11365192, Example 31-1 | 3-[3-[[6-(1H-Pyrazol-5-...)
Affinity DataIC50: 9.30nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558529(US11365192, Example 72-6)
Affinity DataIC50: 9.40nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558114(US11365192, Example 1-19)
Affinity DataIC50: 9.5nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558295(US11365192, Example 31-2)
Affinity DataIC50: 9.80nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558315(US11365192, Example 40-1 | 2-[3-[[6-(5-Oxazolyl)-3...)
Affinity DataIC50: 9.90nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558440(US11365192, Example 59-1 | 1,1,1-Trifluoro-3-[3-[[...)
Affinity DataIC50: 10nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558311(US11365192, Example 38-2 | 2-[3-[[6-(1H-Pyrazol-4-...)
Affinity DataIC50: 11nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558219(US11365192, Example 12-2)
Affinity DataIC50: 11nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558342(US11365192, Example 42-20)
Affinity DataIC50: 11nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558231(US11365192, Example 18-2)
Affinity DataIC50: 12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558297(US11365192, Example 31-4)
Affinity DataIC50: 12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558339(US11365192, Example 42-17)
Affinity DataIC50: 12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558533(US11365192, Example 73-1 | 1,1-Dioxo-3-[8-[6-(1H-p...)
Affinity DataIC50: 12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558326(US11365192, Example 42-4)
Affinity DataIC50: 12nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558265(US11365192, Example 23-2 | N-Methyl-3-[[methyl-[3-...)
Affinity DataIC50: 13nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558222(US11365192, Example 13-2)
Affinity DataIC50: 13nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558230(US11365192, Example 18-1 | 6-[3-[[6-(1H-Pyrazol-5-...)
Affinity DataIC50: 13nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558200(US11365192, Example 8-11)
Affinity DataIC50: 14nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558113(US11365192, Example 1-18)
Affinity DataIC50: 14nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558530(US11365192, Example 72-7)
Affinity DataIC50: 14nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558527(US11365192, Example 72-4)
Affinity DataIC50: 14nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558170(US11365192, Example 2-5 | 3-[2-[2-[[6-(1H-Pyrazol-...)
Affinity DataIC50: 15nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558465(US11365192, Example 71-45 | US11365192, Example 71...)
Affinity DataIC50: 15nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558332(US11365192, Example 42-10)
Affinity DataIC50: 15nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558531(US11365192, Example 72-8)
Affinity DataIC50: 15nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558244(US11365192, Example 22-1 | (2E)-3-[3-[[[6-(1H-Pyra...)
Affinity DataIC50: 15nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558335(US11365192, Example 42-13)
Affinity DataIC50: 15nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558278(US11365192, Example 27-2)
Affinity DataIC50: 15nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558271(US11365192, Example 24-2 | Sodium 2-methyl-2-[3-[[...)
Affinity DataIC50: 16nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558112(US11365192, Example 1-17)
Affinity DataIC50: 16nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558241(US11365192, Example 21-3)
Affinity DataIC50: 16nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4F2(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558452(US11365192, Example 66-1 | 3-[[6-(4-Chloro-1H-pyra...)
Affinity DataIC50: 16nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

TargetCytochrome P450 4A11(Human)
Taisho Pharmaceutical

US Patent
LigandPNGBDBM558115(US11365192, Example 1-20)
Affinity DataIC50: 16nMAssay Description:In the CYP4F2 inhibition test, the reaction solution containing each compound [final concentration of 50 mM, KPO4 (pH 7.4), 2.5 μM luciferine de...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/25/2022
Entry Details
US Patent

Displayed 1 to 50 (of 922 total ) | Next | Last >>
Jump to: